Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ARVN vs ATXS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATXS Captures Overall Composite Edge (57.0 HOLD vs 52.9 HOLD), While ARVN Leads 3–2 on Growth & Valuation Pillars

ATXS Overall Winner 6-Pillar Tally: ARVN 3 – 2 ATXS (1 Tie) Matrix Metrics: ARVN 4 – 6 ATXS

As of Nov 16, 2026, Astria Therapeutics, Inc. (ATXS) captures the overall head-to-head institutional edge over Arvinas, Inc (ARVN) on higher Unified Composite conviction (57.0/100 HOLD vs. 52.9/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Options & Positioning), while ARVN wins 3–2 across the 6-pillar growth and valuation breakdown. ARVN trades at $6.74 (17.9x Forward P/E, -10.1% operating margin) versus ATXS at $12.58 (N/M Forward P/E, -4830.6% operating margin).

  • Growth vs. Quality Trade-Off: ATXS earns the overall head-to-head edge with a stronger Unified Composite Score (57.0/100 HOLD vs. ARVN 52.9/100 HOLD) and 1.26β · 20% Vol risk profile, whereas ARVN leads top-line expansion (-98.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile ATXS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ARVN vs ATXS
ARVN NASDAQ
Arvinas, Inc
Pharmaceutical Preparations
$6.74
-1.17% 1D
Market Cap $449.9M
TTM Revenue $275M
Forward P/E 17.9x
Beta / 30D Vol 1.40β · 66% Vol
Unified Composite Score
52.9 / 100 HOLD
Tech 54.0 Fund 59.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.6%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $7.22 · SMA50: $7.57
ATXS NASDAQ Head-to-Head Winner
Astria Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$12.58
+0.64% 1D
Market Cap $713.6M
TTM Revenue $706,000
Forward P/E N/M
Beta / 30D Vol 1.26β · 20% Vol
Unified Composite Score
57.0 / 100 HOLD
Tech 40.0 Fund 45.0 Flow 50.0 Mom 42.4
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.4 · SMA20: $12.81 · SMA50: $12.74

6-Pillar Scorecard Institutional Category Breakdown (ARVN 3 – 2 ATXS)

Columns: Metric · ARVN · ATXS
1. Valuation Multiples ARVN
Forward P/E 17.9x N/M
Trailing P/E 17.9x N/M
PEG Ratio N/M N/M
EV / Revenue 1.3x N/M
2. Growth & Scale ATXS
Revenue Growth (YoY) -98.8% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $275M $706,000
Market Cap $449.9M $713.6M
3. Profitability & Quality ARVN
Gross Margin 96.7% 100.0%
Operating Margin -10.1% -4830.6%
Net Profit Margin -3.5% 0.0%
Return on Equity (ROE) -1.8% -43.1%
4. Balance Sheet & Cash Flow ARVN
Cash Generation (TTM) -$160M -$32M EBITDA
Cash Flow Margin -58.0% N/A
Net Cash / Leverage $81M Net Cash $2.44 Book/Sh · -43.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ATXS
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 108.7% (25th %ile) 139.9% (50th %ile)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ARVN (4) vs ATXS (6)
Institutional Metric ARVN ATXS Criterion Row Edge
Market Capitalization
Scale
$449.9M $713.6M Larger Scale ATXS
Trailing P/E Ratio
Valuation
17.9x N/M Lower Multiple ARVN
Forward P/E Ratio
Valuation
17.9x N/M Lower Multiple ARVN
Revenue Growth (YoY)
Growth
-98.8% +0.0% Higher Growth ATXS
Operating Margin (TTM)
Profitability
-10.1% -4830.6% Higher Margin ARVN
Net Profit Margin
Profitability
-3.5% 0.0% Higher Margin ATXS
Return on Equity (ROE)
Capital Efficiency
-1.8% -43.1% Higher ROE ARVN
52-Week Range Position
Momentum
5% ($6–$15) 93% ($4–$13) Stronger Trend ATXS
Beta / 30D Volatility
Risk Regime
1.40β · 66% Vol 1.26β · 20% Vol Lower Realized Risk ATXS
Unified Institutional Score
Composite Signal
52.9 / 100 (HOLD) 57.0 / 100 (HOLD) Higher Composite ATXS
Trailing 12M Revenue (USD)
Operating Scale
$275M $706,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
96.7% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$160M ($81M Net Cash) -$32M EBITDA ($2.44 Book/Sh · -43.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ARVN +9.39 pp
ARVN: +7.44% · ATXS: -1.95%
3M Horizon ARVN +23.08 pp
ARVN: +24.21% · ATXS: +1.13%
6M Horizon ARVN +23.08 pp
ARVN: +24.21% · ATXS: +1.13%
1Y Horizon ARVN +23.08 pp
ARVN: +24.21% · ATXS: +1.13%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ARVN vs ATXS. Trailing 12-month operating profitability (ARVN -10.1% vs ATXS -4830.6%) and valuation multiples (ARVN 17.9x vs ATXS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ARVN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$275M
Gross Margin96.7%
Op. Margin-10.1%
ROE / Fwd P/E-1.8% · 17.9x
ATXS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$706,000
Gross Margin100.0%
Op. Margin-4830.6%
ROE / Fwd P/E-43.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ARVN BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 108.7%
IV Percentile 25th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ARVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ATXS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 139.9%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ATXS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ARVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $449.9M market capitalization and -10.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ATXS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $713.6M market capitalization and -4830.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ARVN vs ATXS Key Questions & Quantitative Answers

As of Nov 16, 2026, Astria Therapeutics, Inc. (ATXS) captures the overall head-to-head institutional edge over Arvinas, Inc (ARVN) on higher Unified Composite conviction (57.0/100 HOLD vs. 52.9/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Options & Positioning), while ARVN wins 3–2 across the 6-pillar growth and valuation breakdown. ARVN trades at $6.74 (17.9x Forward P/E, -10.1% operating margin) versus ATXS at $12.58 (N/M Forward P/E, -4830.6% operating margin). Growth vs. Quality Trade-Off: ATXS earns the overall head-to-head edge with a stronger Unified Composite Score (57.0/100 HOLD vs. ARVN 52.9/100 HOLD) and 1.26β · 20% Vol risk profile, whereas ARVN leads top-line expansion (-98.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ARVN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7); meanwhile ATXS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ATXS leads the Growth & Scale pillar: ARVN posts -98.8% YoY revenue growth and +0.0% YoY earnings growth on $275M TTM revenue (96.7% gross margin, -10.1% operating margin), compared with ATXS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $706,000 TTM revenue (100.0% gross margin, -4830.6% operating margin). On trailing 12-month operating scale, ARVN generates $275M in USD-normalized revenue versus $706,000 for ATXS. In operating R&D and SG&A reinvestment, ARVN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATXS.

ARVN screens cheaper on headline valuation multiples. ARVN trades at 17.9x Forward P/E, 17.9x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-58.0% FCF margin), whereas ATXS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARVN (-1.8% ROE) versus ATXS (-43.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ARVN carries 108.7% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 66% Vol realized risk). By comparison, ATXS carries 139.9% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.26β · 20% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.